Table 2. MicroRNA (miRNA) evaluation in current prospective clinical trials.
| Study | Type of study |
Intervention | Line | Patients | Serum miRNA | Timing | ClinicalTrials. gov Identifier |
|---|---|---|---|---|---|---|---|
| AGCT1531 | Phase III | Active Surveillance |
NA | Low-risk Stage I |
• Correlation of miRNA levels and stage I relapse |
• Pre orchidectomy • Every 1 month × 3 • Every 3 months for 1 year • Every 6 months for 1 year |
NCT03067181 |
| Carboplatin versus cisplatin (+ etoposide, bleomycin) |
I | Standard-risk Metastatic |
• Marker decline on treatment • Identification prognostic miRNAs |
Not available | |||
| UKP3BEP | Phase III randomised |
Accelerated versus standard BEP (bleomycin, etoposide and platinum) chemotherapy |
I | Intermediate/ poor-risk Metastatic/ Mediastinal primary |
• Marker decline on treatment • Identification prognostic miRNAs |
• Day 1 • Day 22 • Day 43 • End of treatment • 1 year |
NCT02582697 |
| SWOG S1823 |
Prospective cohort study |
Surveillance | NA | Stage I | • Correlation of miR-371a-3p levels and stage I relapse |
• Pre-orchidectomy • Post-orchidectomy • 3 monthly (for 2 years) |
NCT04435756 |
NA, not applicable.